An analysis of recent US drug sales confirms the growing role of licensing and acquisitions, though the biggest sellers conceal some interesting nuance.
Yesterday’s high-profile presentation of the Regenerate trial failed to quash concerns about Ocaliva in Nash, despite Intercept’s best attempts to polish the data.
Survival data confirm the value of Astellas’s FLT3-targeting approach in acute myelogenous leukaemia.
The price in value-based payment deals should by definition be justified, so why is patient cost-sharing part of the calculation? Spark covers this cost, but there is no…
Pfizer/Merck KGaA scrap a pivotal trial, partly because it tested Bavencio against what is no longer the relevant standard of care.
Fears about flattening Opdivo sales were surely a major driver for Bristol's move for Celgene. To keep growing the checkpoint inhibitor needs some big clinical wins.
Amarin and Esperion get a chance to reinforce their lipid-lowering candidates, while a Bayer heart failure project gets a high-profile slot despite its discontinuation.
A positive readout for Medtronic's Tyrx envelope could mean an extra $1,000 per cardiac implant in the company's pocket.
Guardant gets a liquid biopsy trial win, but if it wants to drive sales it must get cancer societies on board.